Product Information & Dosing

NIVESTYM is the first and only FDA-approved Neupogen biosimilar available in both prefilled syringes and single-dose vials1
 
NIVESTYM has an identical dosing schedule and route of administration as Neupogen1
Recommended starting doses in adults and children receiving chemotherapy for acute myelogenous leukemia (AML)1
Recommended starting doses in patients receiving bone marrow transplant (BMT)1
Recommended starting doses in patients with peripheral blood progenitor cell collection and therapy (PBPC)1
Recommended starting doses in patients with severe chronic neutropenia (SCN)1